TraceLink boosts leadership position

Track-and-trace network exceeds 200,000 supply chain members

Register for free to listen to this article
Listen with Speechify
0:00
5:00
NORTH READING, Mass.—Mid-January saw TraceLink Inc., a track-and-trace network for connecting the life-sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, announce that its Life Sciences Cloud has exceeded more than 200,000 connected members across the global pharmaceutical supply chain.
 
According to TraceLink, a single connection to the Life Sciences Cloud allows pharmaceutical manufacturers, contract manufacturing organizations (CMOs), distributors and dispensers of any size to connect with any trading partner that is already configured on the network and instantly begin sharing documents and data for regulatory compliance. In addition, the company’s 15 commercially available drug traceability solutions are now used by pharmaceutical suppliers in global markets that account for 75 percent of the world’s drug supply.
 
“The unique approach we’ve taken with our network model is what sets TraceLink apart, and continues to fuel our success,” said Shabbir Dahod, president and CEO of TraceLink. “Other vendors suggest that on-premise systems and single-tenant architectures can address the complex compliance challenges facing the industry, but the reality is that these approaches just can’t scale to meet the serialization processing and data exchange demands of the new regulatory laws. Our track-and-trace network is proven to accelerate the ability for any pharmaceutical manufacturer, distributor or dispenser to achieve regulatory compliance with the least cost, time and risk, which is why we’ve been able to grow our network from a few thousand suppliers to more than 200,000 in a little over a year.”
 
Built on the Amazon Web Services global cloud infrastructure as a native cloud-based application, the TraceLink Life Science Cloud uses on-demand computing resources and database architectures specifically designed to handle a massive amount of real-time compliance data across thousands of network connections in ways that traditional, on-premise systems and relational databases cannot.
 
With the rapid growth of the TraceLink Life Sciences Cloud, pharmaceutical companies seeking efficient and cost-effective ways to connect with their suppliers typically find that over 90 percent of the trading partners they do business with are already on the TraceLink network, according to the company. Select benefits of the TraceLink network include:
  • Seamless integration with trade partners, enabling companies to connect once and integrate to all of their suppliers on the network, by publishing services, registering members and configuring maps for integrating collaborative business processes
  • A modern, distributed NoSQL architecture—running simultaneously across multiple data centers and providing the fastest processing for billions of serial number objects and transaction documents
  • Access to more than 680 CMOs, serving as the world’s largest collection of contract manufacturers that are integrating with TraceLink’s pharmaceutical manufacturing customers
  • Automatic provisioning for greater capacity, based on the unique processing demands of users, with no additional cost for increases or decreases to capacity
  • Instant software updates for compliance coverage, ensuring that as regulations change, every trade partner has immediate access to any updates that will maintain compliance across the supply chain.
A winner of numerous industry awards including the Amazon AWS Global Start-Up Challenge Grand Prize and the Edison Award for Innovation in Health Management, the TraceLink Life Sciences Cloud is used by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost.


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue